Accéder au contenu
Merck

The pharmacokinetics of nevirapine when given with isoniazid in South African HIV-infected individuals.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease (2013-02-15)
E H Decloedt, J Mwansa-Kambafwile, J-S van der Walt, H McIlleron, P Denti, P Smith, L Wiesner, M Rangaka, R J Wilkinson, G Maartens
RÉSUMÉ

Isoniazid preventive therapy (IPT) is recommended in patients on antiretroviral treatment. Isoniazid (INH) inhibits CYP3A4, which metabolises nevirapine (NVP). Administration of INH may cause higher NVP concentrations and toxicity. We studied the effect of INH on NVP concentrations in 21 patients randomised to either placebo (n = 13) or INH (n = 8) in an ongoing trial of IPT in patients on ART. INH was associated with a 24% increase in median NVP area under the plasma concentration-time curve for the 12 h dosing interval, which was not statistically significant (P = 0.66).

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Nevirapine